Results 211 to 220 of about 7,594,057 (369)

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

open access: yesNew England Journal of Medicine, 2017
T. Mok   +16 more
semanticscholar   +1 more source

AAPM medical physics practice guideline 13.a: HDR brachytherapy, part B

open access: yesJournal of Applied Clinical Medical Physics, EarlyView.
Abstract The goal of this report is to assist the clinical medical physicist in assuring that key quality standards and practice considerations are met to ensure safe, reliable, and reproducible high dose rate (HDR) brachytherapy (BT) treatment. This guideline has been developed to provide appropriate minimum standards for such services.
Susan L. Richardson   +8 more
wiley   +1 more source

Automated rapidplan model validation using Eclipse scripting API

open access: yesJournal of Applied Clinical Medical Physics, EarlyView.
Abstract RapidPlan offers efficiency gains and quality improvements in treatment planning. Prior to its use in the clinic, it requires an extensive validation procedure in which established clinical plans and those generated by the model are compared. The manual iterative nature of this process is resource intensive, as numerous iterations are required
Bradley Beeksma   +2 more
wiley   +1 more source

Demonstration of an enhanced dosing pattern for debulking large and bulky unresectable tumors via differential hole‐size spatially fractionated radiotherapy

open access: yesJournal of Applied Clinical Medical Physics, EarlyView.
Abstract Purpose/objective We propose a novel lattice deployment for spatially fractionated radiotherapy (SFRT) treatments. In this approach, a larger diameter high‐dose sphere is centrally placed in the bulky tumor mass and surrounded by smaller diameter high‐dose spheres.
Joshua Misa   +2 more
wiley   +1 more source

Lung cancer screening in limited resource regions: the 3rd Brazilian Early Lung Cancer Trial (BRELT3/mobile ProPulmão). [PDF]

open access: yesLung Cancer Manag
Santos RSD   +28 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy